

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

**Interpretive Summary**

New opportunities of cancer prevention through changes in diet regimens can be developed from the increasing knowledge of food components effects on health. Consumption of milk and dairy products, as well as lactoferrin enriched food may prevent the development of breast cancer, by the decrease of cancer cell viability and proliferation, increase of apoptosis levels and decrease of cancer cell migration.

**Running title:** Lactoferrin & Breast Cancer

**The effect of bovine milk lactoferrin on human breast cancer cell lines**

**D. C. Duarte<sup>\*</sup>, A. Nicolau<sup>\*</sup>, J. A. Teixeira<sup>\*</sup>, L. R. Rodrigues<sup>\*†</sup>**

<sup>\*</sup> IBB – Institute for Biotechnology and Bioengineering, Centre of Biological Engineering, Campus de Gualtar, 4710-057 Braga, Portugal

---

<sup>†</sup> Corresponding author: L.R. Rodrigues  
Phone: +351253604400; Fax: +351253678986  
Email: [lrmr@deb.uminho.pt](mailto:lrmr@deb.uminho.pt)

23

24

## ABSTRACT

25 The evidence that biologically active food components are key environmental factors  
26 affecting the incidence of many chronic diseases is overwhelming. However, the full  
27 extent of such components in our diet is unknown, as well as our understanding of their  
28 mechanisms of action. Beyond their interaction with the gut and intestinal immune  
29 functions, more benefits are being tested for whey proteins such as lactoferrin, namely  
30 as anti-cancer agents. Lactoferrin is an iron-binding protein that has been reported to  
31 inhibit several types of cancer. In the present work, the effects of bovine milk lactoferrin  
32 on human breast cancer HS578T and T47D cells were studied. The cells were either  
33 untreated or submitted to lactoferrin concentrations ranging from 0.125 to 125  $\mu$ M.  
34 Lactoferrin decreased 47% and 54% the cell viability of HS578T and T47D,  
35 respectively, and increased apoptosis about twofold for both cell lines. Proliferation  
36 rates decreased between 40.3 and 63.9% for HS578T and T47D, respectively. T47D cell  
37 migration decreased in the presence of the protein. Although the mechanisms of action  
38 have still not been unveiled, the results gathered in this work suggest that lactoferrin  
39 interferes with some of the most important steps involved in cancer development.

40

41 **Key words:** lactoferrin, breast cancer, viability and proliferation, apoptosis and migration

42

43

44

## INTRODUCTION

45

46 Milk and dairy products have become recognized as functional foods, suggesting  
47 their use has a direct and measurable effect on health outcomes, namely that their  
48 consumption has been related with a reduced risk of numerous cancers (Marshall,  
49 2004). Cancer is the second leading cause of mortality worldwide, with an expected 1.4  
50 million persons being diagnosed with breast cancer in 2010. Hence, this is an  
51 enormously important health risk, and progress leading to enhanced survival is a global  
52 priority (Jemal et al., 2009; Schiff and Osborne, 2005).

53

54 Breast cancer, like all the other cancer types, is a result of six essential  
55 alterations in normal cells that represent good targets for treatment; the so-called cancer  
56 hallmarks (Hanahan and Weinberg, 2000). These include the ability to be self-sufficient  
57 in growth signals (tumor cells present reduced dependence on exogenous growth  
58 stimulation); to evade anti-growth signs and apoptosis; to achieve endless replicative  
59 potential; to sustain angiogenesis; to evade tissues, and to form metastasis. Several  
60 strategies have been pursued in the last years in order to hamper the development of  
tumors or treat existing ones (Hanahan and Weinberg, 2000).

61

62 An increasing interest has been reported on the use of biologically active  
63 substances from food (Ferguson 2009; Gill et al., 2000; Jacobs et al., 2009; McCabe-  
64 Sellers et al., 2009; Perdigon et al., 2002; Tsuda et al. 2004). However, the full set of  
65 active components in our diet is unknown and the knowledge on their mechanisms of  
66 action is scarce. Proteins and peptides existing in milk have been reported to be cancer  
67 preventive agents (Korhonen and Pihlanto, 2006; Rodrigues et al., 2009; Tsuda et al.,  
68 2000; Wakabayashi et al., 2006), such as lactoferrin (**LF**), that is also known for its  
69 inhibitory action on cell proliferation, as well as for its anti-inflammatory and  
70 antioxidant abilities (Iigo et al., 2009; Legrand et al., 2005; Pan et al., 2007; Rodrigues  
et al., 2009; Tomita et al., 2002; Tsuda et al., 2002, 2010; Ward et al., 2005).

71

72 LF is an iron-binding glycoprotein from the transferrin family that can be found  
73 in many different tissues or secretions, such as tears, saliva, blood, secondary granules  
74 of neutrophils and milk (Rodrigues et al., 2009; Pan et al., 2007; Tsuda et al., 2002). *In*  
75 *vivo* studies showed that oral administration of bovine LF to rodents significantly  
reduces chemically induced tumorigenesis in different organs (breast, esophagus,

76 tongue, lung, liver, colon and bladder) and inhibits angiogenesis (Iigo et al., 2009;  
77 Tsuda et al., 2002). It has been demonstrated that more than 60% of administrated  
78 bovine LF survived passage through the adult human stomach and entered the small  
79 intestine in an intact form (Troost et al., 2001). Intact and partly intact bovine LF are  
80 likely to exert various physiological effects in the digestive tract. Moreover,  
81 subcutaneously administration of LF inhibited the growth of implanted solid tumors and  
82 exerted preventive effects on metastasis (Bezault et al., 1994).

83         These activities of LF have been attributed to its immunomodulatory potential  
84 and ability to activate T and NK cells (Bezault et al., 1994; Damiens et al., 1999). LF is  
85 able to limit the growth of tumor cells and it was shown that addition of exogenous LF  
86 to MDA-MB-231 breast cancer cell lines culture media induced the cell cycle arrest at  
87 the G1/S transition (Damiens et al., 1999). Also, LF was found to induce growth arrest  
88 and nuclear accumulation of Smad-2 in HeLa cells (Zemann et al., 2010). According to  
89 Babina and coworkers (2005), LF possesses DNase activity and; is cytotoxic,  
90 suppressing the growth of several human and mouse cell lines. Recent studies  
91 demonstrated that LF has an estrogen element of response (ERE) (Teng, 2006) that  
92 confers the protein the ability to interfere with the genetic expression of several  
93 molecules that are vital for cell survival. Furthermore, LF was found to induce apoptosis  
94 in several human cell lines, as for example A459 lung cells, CaCO-2 intestine cells and  
95 HTB9 kidney cells (Hakansson et al., 1995), and to inhibit Akt activation and modulate  
96 its downstream proteins phosphorylation in apoptosis of SGC-7901 human stomach  
97 cancer cells (Xu et al., 2010). Moreover, LF was effective against melanoma cells (Pan  
98 et al., 2007), decreasing the proliferation rates and increasing apoptosis levels. Xiao and  
99 coworkers (2004) also reported LF's inhibitory effects on head and neck cancer cells,  
100 down-regulating G1 cyclin-dependent kinases, and therefore influencing the cell cycle.  
101 Finally, LF has been reported to suppress cell-induced angiogenesis in mice, and to  
102 increase the IL-18 production (Xiao et al., 2004).

103         Knowledge on the effect of diet components on health will put forward new  
104 opportunities for cancer prevention through profound alterations in the diet regimens.  
105 Over time, small but recurrent doses of bioactive proteins may prevent the carcinogenic  
106 process by decreasing the rate of cell proliferation and growth of cancer cells. In the  
107 current work, the effect of a range of LF concentrations at different exposure times on  
108 cell viability, proliferation, apoptosis and migration using two model human breast  
109 cancer cell lines, HS578S and T47D, was studied. The rationale of using two cell lines

110 is due to their differences in the estrogen receptor. The cells lacking the estrogen  
111 receptor (e.g. HS578T) usually correspond to more aggressive type of tumors for which the  
112 existent therapy is not very efficient. Therefore, for these type cells, if LF shows an effect it  
113 would represent an important scientific advance. On the other hand, for cells that possess the  
114 estrogen receptor (e.g. T47D), if an effect is proved for LF, then a combination with  
115 estrogen could be further explored for breast cancer therapeutics.

116

117

## MATERIALS AND METHODS

118

### 119 *Lactoferrin*

120 Lactoferrin (**LF**) (Sigma-Aldrich Co., St. Louis, MO) was dissolved in phosphate saline  
121 buffer (**PBS**) (PBS: 1g/L NaCl, 0.2g/L KCl, 0.24g/L Na<sub>2</sub>HPO<sub>4</sub>·2H<sub>2</sub>O, 1.805g/L  
122 KH<sub>2</sub>PO<sub>4</sub>, pH 7.4) in order to obtain different protein solution concentrations (0.125,  
123 6.25, 12.5 and 125 μM). All LF solutions were passed through a 0.2-μm filter prior to  
124 use, and stored at 4°C.

125

### 126 *Breast Cancer Cell Lines*

127 Breast cancer cell lines, HS578T and T47D, were kindly provided by IPATIMUP  
128 (Portugal). The HS578T cell strain was derived from a carcinoma of the breast and is  
129 negative for estrogen receptor (**ER-**). The T47D line was isolated from a pleural  
130 effusion obtained from a 54 year old female patient with an infiltrating ductal carcinoma  
131 of the breast and is positive for estrogen receptor (**ER+**). The cells were maintained in  
132 an incubator with a 5% CO<sub>2</sub> atmosphere and at 37°C. The culture medium used was the  
133 Dulbecco's modified Eagle medium (**DMEM**) (GIBCO®, Invitrogen, Barcelona,  
134 Spain) supplemented with 10% of Fetal Bovine Serum (**FBS**) (GIBCO®, Invitrogen,  
135 Barcelona, Spain) and 1% of penicillin/streptomycin (Invitrogen, Barcelona, Spain).

136

### 137 *Cell Viability*

138 Two distinct methods were used to evaluate the cell viability to LF exposure as  
139 described below.

140

141 ***Trypan blue method***

142 Cells were grown in 6-well plates until a concentration of  $1 \times 10^5$  cells per well was  
143 achieved. Adequate volumes of the previously prepared LF solutions were added to  
144 each well, in order to obtain the required LF concentrations (0.125, 6.25, 12.5 and 125  
145  $\mu\text{M}$ ). Additionally, control wells were included consisting of DMEM medium and PBS  
146 (no LF added). The plates were incubated for 24, 48 and 72 hours. Subsequently, the  
147 supernatant of each well was collected to a falcon tube. The adhered cells were washed  
148 with PBS, trypsinized, and then collected to the respective falcon. All falcons were  
149 centrifuged (700 x g, 5 minutes) and the supernatant was discharged. The remaining  
150 pellet was resuspended in 100  $\mu\text{l}$  of PBS. The collected cell volumes were diluted 1:1  
151 with Trypan Blue (**TB**) (Sigma-Aldrich Co., St. Louis, MO), and the viable and non-  
152 viable cells were counted in a Neubauer chamber, using an inverted optical microscope  
153 equipped with a 20X objective. The results are expressed as percentage of viable cells  
154 as compared to the control and represent an average of 3 independent cultures with 8  
155 wells per concentration in each experiment.

156

157 ***MTS method***

158 The cell viability to LF exposure was also determined using the **MTS** (3-(4,5-  
159 dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)  
160 method. A commercial kit was used according to the manufacturer instructions  
161 (Promega, PROM G35800001, Lisbon, Portugal). In these experiments, 100  $\mu\text{l}$  of cell  
162 suspension was added to each well of a 96-well plate. Additionally, control wells were  
163 included consisting of DMEM medium and PBS. When a cell concentration of  $1 \times 10^5$   
164 cells/ml was obtained, adequate volumes of LF solutions were added to the wells and  
165 incubated for different exposure times (24, 48 and 72 hours). Afterwards, 20  $\mu\text{l}$  of the  
166 CellTiter 96 AQueous One Solution Cell Proliferation Assay reagent (**MTS**) was added  
167 to each well and left in the incubator (37°C, 5%  $\text{CO}_2$ ) for 3 hours after which the cell  
168 viability was quantified by recording the absorbance at 490 nm. The results are  
169 expressed as percentage of viable cells compared to the control and represent an average  
170 of 3 independent cultures with 8 wells per concentration in each experiment.

171

172

173 ***Apoptosis***

174 The effect of different LF concentrations (0.125, 6.25, 12.5 and 125  $\mu\text{M}$ ) and exposure  
175 times (24, 48 and 72 h) in cell apoptosis was accessed using a commercial kit (Promega,  
176 PROM G 8091, Lisbon, Portugal) with the same experimental setup as described above.  
177 After exposing the cells, in a concentration of  $1 \times 10^4$  cells/ml, to LF (37°C, 5%  $\text{CO}_2$ ),  
178 100  $\mu\text{l}$  of Caspase-Glo 3/7 reagent was added to the wells, and after 3 hours standing at  
179 room temperature and in the dark, the apoptosis levels were determined by  
180 luminescence recording. The average blank value (DMEM medium alone) was 2845  
181 Relative Luminescence Units (**RLU**) and 642 RLU for the experiments conducted with  
182 T47D and HS578T, respectively. The blank value was subtracted from all the other  
183 values. The luminescence of the cells in medium (control) lay above this value and is  
184 given by 0  $\mu\text{M}$  LF. The results represent an average of 3 independent cultures with 8  
185 wells per concentration in each experiment.

186

187 ***Cell Proliferation***

188 Cell proliferation was determined using the bromodeoxyuridine (5-bromo-2-  
189 deoxyuridine, **BrdU**) (Sigma-Aldrich Co., St. Louis, MO) assay. Briefly, a lamella was  
190 placed in each well of a 24-well plate and cells were grown until a cell concentration of  
191  $1 \times 10^5$  cells per well was achieved. These experiments were conducted for 12.5  $\mu\text{M}$  LF.  
192 After 48 h of exposure to LF, 50  $\mu\text{l}$  of BrdU per ml of culture medium was added to each  
193 well and the plates were incubated (37°C, 5%  $\text{CO}_2$ ) for 3 hours. Afterwards, the cells  
194 were washed with PBS and left at 4°C in 1ml of paraformaldehyd 1% w/v (prepared in  
195 PBS). Subsequently, the fixed cells were treated with HCl 2M at room temperature for  
196 30 minutes. Next, the lamellas were washed with PBS-0.5% Tween20-0.05% bovine  
197 serum albumin (**BSA**), and incubated with anti-BrdU (mouse) (DAKO Denmark,  
198 Denmark) at a 1:1 dilution with PBS-0.5% Tween20-0.05% BSA. After 1 h, lamellas  
199 were washed twice with PBS-0.5% Tween20-0.05% BSA, and subsequently incubated  
200 with anti-mouse Ig fluorescein isothiocyanate (**FITC**) (DAKO Denmark, Denmark) at a  
201 1:100 dilution in PBS-0.5% Tween20-0.05% BSA for 30 minutes. Finally, the lamellas  
202 were washed with PBS-0.5% Tween20-0.05% BSA. The nuclei were counted in a  
203 fluorescence microscope (Zeiss HBO-50) using a 40X magnification. The total number

204 of nuclei was marked with 4',6-diamidino-2-phenylindole (**DAPI**) (blue) and the ones in  
205 proliferation were marked with FITC (green). Proliferation rates were determined as the  
206 percentage ratio between the number of nuclei in proliferation and total number of  
207 nuclei. The results represent an average of 3 independent cultures and 10 measures for  
208 each culture.

209

### 210 *Migration*

211 A suspension containing  $1 \times 10^5$  cells was left to grow in 6-well plates, until 90%  
212 confluence was achieved. Next, adhered cells were washed twice with PBS. Afterwards,  
213 a wound was inflicted in the center of each well, with the help of a needle, and 3 spots  
214 were marked on the wound as reference points. Then, fresh DMEM medium was added  
215 to the wells, and also the adequate volume of LF solution to obtain a 12.5  $\mu\text{M}$   
216 concentration. During the 48 h of exposure, pictures were taken at the pre-defined  
217 measuring spots using an inverted microscope (Nikon Diaphot 300, Sony, Portugal)  
218 equipped with a 20X objective. The images were captured by a video camera (Sony  
219 CCD, Sony, Portugal) and processed using the Image Pro-Plus® version 7.0 software  
220 (Media Cybernetics, Bethesda, MD) which allowed the measurement of the distance (in  
221 micrometers ( $\mu\text{m}$ )) over time between the front cells in each edge of the wound. These  
222 distances correspond to an average of 3 independent cultures and 9 measures for each  
223 culture.

224

### 225 *Statistical Analysis*

226 Two-tailed unpaired Student's t-test was used for the statistical evaluation of significant  
227 differences among the tested LF concentrations and exposure times as compared to the  
228 control. Statistical analyses were performed in Microsoft Office Excel 2007 (Seattle,  
229 WA).

230

231

## **RESULTS**

232

### 233 *Cell Viability*



234 ***Trypan blue method***

235 The trypan blue (TB) method enables distinguishing viable cells from dead cells, since  
236 dead cells are permeable to the dye and will be colored blue. The results obtained are  
237 compiled in Table 1. A decrease over 50% in the number of viable cells was obtained  
238 for increasing LF concentrations and exposure times, for both cell lines studied. Based  
239 on these experiments, 12.5  $\mu\text{M}$  LF was found to be effective in decreasing T47D cell  
240 viability as compared to the control (set at 100%) between 28 and 54%, depending on  
241 the exposure time. The differences obtained for the range of LF concentrations studied,  
242 as compared to the control, were found to be statistically significant, except for 0.125  
243  $\mu\text{M}$ . Furthermore, the  $p$ -values obtained when comparing the different exposure times,  
244 namely 24 and 48 h, 48 and 72 h, 24 and 72 h, were 0.06, 0.08 and 0.05, respectively.  
245 For the HS578T cell line, the conditions that promoted a more pronounced decrease of  
246 cell viability were 72 h exposure to 125  $\mu\text{M}$  LF. Nevertheless, at this exposure time and  
247 LF concentration, cellular lysis was observed (*data not shown*). Comparing to the  
248 control, 12.5  $\mu\text{M}$  LF decreased HS578T cell viability between 18 and 47%, depending  
249 on the exposure time. The differences obtained for all the LF concentrations studied  
250 were found to be statistically significant. Also, comparing the different exposure times,  
251 the differences obtained between 24 and 48 h were not statistically significant ( $p$ -value  
252 = 0.14), while the  $p$ -values obtained for 48 and 72 h, and 24 and 72 h comparisons were  
253 0.02 and 0.03, respectively.

254

255 ***MTS method***

256 The MTS assay is assumed to reflect cell number and is used to determine exposure-  
257 response relationships. Table 1 presents the results obtained in the MTS assays.  
258 Although slightly higher reductions on cell viability were found with this method,  
259 especially for 72 h, the tendencies were similar, thus these results were found to be in  
260 agreement with the ones obtained with the TB dye method. Statistical significance was  
261 found for the comparisons between the different exposure times and the different LF  
262 concentrations used.

263

264 ***Apoptosis***

265 LF influence in apoptosis was assessed by measuring caspase 3 and 7 activities, since  
266 these are the effectors of the apoptosis machinery. LF increasing concentrations were  
267 found to increase such activities for both cell lines, as can be observed in Fig. 1.  
268 Generally, it was found that for a 72 h exposure a decrease in apoptosis occurs. This  
269 result coincides with the cellular lysis observed in the cell viability assays as described  
270 above. Although cell death was higher for a 72 h exposure to LF, necrosis was found to  
271 be the principal cellular death process occurring for this exposure time. For both cell  
272 lines, the caspases 3/7 activity increased about 1.5-2 times for the lower LF  
273 concentrations studied (except for the concentration 0.125  $\mu$ M LF in the HS578T  
274 assays), being the differences observed, as compared to the control, statistically  
275 significant. An increase of about 3-5 times in the apoptotic levels was obtained in the  
276 experiments conducted with 125  $\mu$ M LF. It is important to notice that the differences  
277 observed between the different exposure times were in most of the cases not statistically  
278 significant.

279

### 280 ***Cell Proliferation***

281 Based on the results from MTT, TB and apoptosis assays, a 48 h exposure to 12.5  $\mu$ M  
282 LF was chosen for the cell proliferation experiments. The effect of LF on cell  
283 proliferation was studied using BrdU, a synthetic thymidine analogue that binds to new-  
284 formed DNA in S-phase, thus allowing the determination of the nuclei in proliferation.  
285 As expected from the previous results, LF was found to decrease the proliferation rates  
286 for both cell lines (Fig. 2). Proliferation rate decreases of 35.5% and 52.5% were  
287 obtained for HS578T and T47D, respectively. The differences observed for the  
288 proliferation rates as compared to the control experiments were found to be statistically  
289 significant for both cell lines ( $p < 0.005$  for HS578T and  $p < 0.0005$  for T47D).

290

### 291 ***Migration***

292 The LF concentration and exposure time used in the migration experiments were the  
293 same as the ones used to study cell proliferation. LF was found to decrease the  
294 migration of both cell lines used (Fig. 3 and Fig. 4) being this effect more pronounced  
295 for T47D. From the statistical analysis, the differences observed for HS578T cells  
296 treated and untreated were not significant ( $p = 0.116$ ). Nevertheless, the differences

297 observed for T47D were statistically significant ( $p = 0.001$ ). The distance ( $\mu\text{m}$ ) between  
298 the front cells in each edge of the wound was higher for the cells exposed to 12.5  $\mu\text{M}$   
299 LF during 48 h, as compared to the control (with no LF added).

300

301

## DISCUSSION

302

303 The role of milk proteins and peptides as physiologically active factors in the diet is  
304 being increasingly acknowledged (Marshall, 2004). Environmental factors, such as food  
305 and physical activity, have an important influence on the risk of cancer, thus delayed  
306 cancer development may be obtained by changing diet regimens. A large amount of data  
307 regarding the bioactivity of food components have been obtained using cell lines, and  
308 an important question regarding much of this work is the relevance of the  
309 concentrations used (Petricoin and Liotta, 2003).

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

In the current work, the influence of LF on cell viability for both cell lines was studied using two complementary tests, namely the TB dye method and the bio-reduction of the MTS reagent (Table 1). Some cytotoxicity assays allow the immediate interpretation of the results, such as the incorporation of a dye by dead cells, release of  $^{51}\text{Cr}$  or fluorescein from pre-labeled cells. These assays are viability assays and intend to predict survival and not directly assessing it, since they are good for identifying dead cells but can overestimate survival in the long term. Most of these assays involve the cell membrane rupture and cell death. Cell viability is a measure of the metabolic status of a population and gives an indication of its growth potential. One of the simplest methods to evaluate cell viability is the dye exclusion approach, indicating the cellular membrane capacity to exclude a dye. The most commonly used dye is TB, and the method is based on the concept that viable cells do not absorb certain dyes while dead cells are permeable to them. Nevertheless, this method presents some disadvantages, such as also dying soluble proteins; causing stress to the cells, as well as being influenced by the presence of serum. Therefore, in this work a complementary test for assessing cell viability was included. The results obtained showed a decrease over 50% in the number of viable cells for increasing LF concentrations and exposure times, for both cell lines studied. Although the results pointed to 72 hours of exposure to 125  $\mu\text{M}$  LF to be the most effective conditions regarding a decrease in cell viability, at these conditions cellular lysis was observed. For that reason, and since cellular lysis is

330 frequently associated with necrosis, such information was taken into consideration for  
331 the choice of the conditions to use (12.5  $\mu$ M LF was fixed at 48 h) in the following  
332 experiments (proliferation and migration). Once necrosis occurs, the cellular content  
333 is spilled into the surrounding tissues, causing inflammation and contamination of the  
334 neighbor cells with carcinogenic products. Therefore, the occurrence of necrosis is a  
335 nonfavorable factor when the goal is treating cancer (Werner et al., 2005).

336 The results obtained in these experiments are in accordance with data previously  
337 reported for LF effects on other human cancer cell lines (Hakansson et al., 1995; Tsuda  
338 et al., 2004; Xiao et al., 2004). As described above, there are other viability assays, such  
339 as the bio-reduction of the MTS reagent, that measure the metabolic events occurring in  
340 the cell, allowing a more precise quantification since they are more sensitive. These  
341 reductions take place only when reductase enzymes are active, and therefore conversion  
342 is often used as a measure of viable cells. However, these colorimetric assays also  
343 present disadvantages regarding interferences from the culture medium, reversible  
344 metabolic inhibitions and different colorimetric responses for different types of cells.  
345 Also, it is important to keep in mind that other viability tests sometimes give completely  
346 different results, as many different conditions can increase or decrease metabolic  
347 activity. Changes in metabolic activity can give large changes in MTS results while the  
348 number of viable cells is constant. When the amount of purple formazan produced by  
349 cells treated with an agent, such as LF, is compared with the amount of formazan  
350 produced by untreated control cells, the effectiveness of the agent causing death, or  
351 changing metabolism of cells, can be deduced through a dose-response curve. Results  
352 gathered from these experiments were similar to the ones obtained with the TB method.  
353 Furthermore, it is important to notice that, although the higher LF concentration studied  
354 (125  $\mu$ M) was the most effective, this concentration, considering that a major part of  
355 ingested LF survives passage through the gut (Troost et al., 2001), would represent an  
356 unreasonable daily intake of milk or dairy products. Therefore, 12.5  $\mu$ M LF was chosen  
357 for the subsequent experiments.

358 Cell viability usually results from the balance between cell growth/proliferation  
359 and cell death. Also, cell death can occur by one of two different mechanisms, namely  
360 necrosis and/or apoptosis (Werner et al., 2005). Cells undergoing apoptosis are  
361 characterized by cell shrinkage, chromatin condensation, DNA fragmentation and  
362 membrane disassembling (Hakansson et al., 1995; Mader et al., 2005). Two main

363 pathways have been reported to mediate apoptosis (Mader et al., 2005). One is the death  
364 receptor pathway which is triggered by ligand-inducing aggregation of death receptors,  
365 such as the Fas protein (Fujita et al., 2004). The second pathway is related with the  
366 activation of mitochondria response to cytotoxic drug-induced cellular stress (Mader et  
367 al., 2005). The results clearly showed an effect of LF in the apoptotic levels based on  
368 the activities of caspase 3 and 7 (effectors of the apoptosis machinery), and confirmed  
369 the cellular lysis occurring for the 72 hours of exposure to the higher protein  
370 concentration used. According to Sakai and coworkers (2005), pepsin-digested bovine  
371 LF influences the apoptosis machinery by activating the JK-SAPK signalling pathway  
372 in human oral squamous cell carcinoma cell line SAS. The authors found that treatment  
373 with pepsin-digested bovine LF induced cell death with apoptotic nuclear changes  
374 preceded by the cleavage of caspase-3 and poly (ADP-ribose) polymerase (**PARP**) in  
375 the apoptotic cells. Moreover, the peptide induced phosphorylation of extracellular  
376 signal-regulated kinase (**ERK1/2**), a member of the MAP kinase family, at early stages  
377 of apoptosis. Another MAP kinase, c-Jun N-terminal kinase/stress-activated protein  
378 kinase (**JNK/SAPK**), was also phosphorylated by treatment with pepsin-digested LF.  
379 Also, other authors (Hakansson et al., 1995; Roy et al., 2002) reported that LF and  
380 related compounds induce the genetic expression of Fas (Fujita et al., 2004), which is  
381 involved in apoptosis triggering. Roy and collaborators determined the effects of LF and  
382 several protein hydrolysates on the growth of human myeloid leukemic cells (HL-60).  
383 In their studies they showed that bovine milk contains biochemical factors with potent  
384 cytotoxic properties against some tumor cells and, that the key factors are mostly  
385 inactive within the structure of the precursor compounds, but can be released by  
386 enzymatic proteolysis. Also, a report from Tomita and collaborators (1994) provided  
387 evidence of *in vivo* production of lactoferricin B by isolating the peptide from the  
388 gastrointestinal contents of rats fed a diet containing bovine LF. Based on these  
389 evidences, it is likely that the activity of LF in apoptosis and cell growth is due mostly  
390 to its major peptide (lactoferricin) and therefore, further studies to clarify the possible  
391 mechanisms involved, as well as if LF could be degraded and to what extent in the cells  
392 culture medium, are required.

393 As mentioned previously, cell proliferation is also an important factor affecting  
394 cell viability. As expected from the cell viability tests and apoptosis study, proliferation  
395 rates were found to decrease for both cell lines when exposed to LF, being this effect  
396 more pronounced for T47D. According to Xiao and coworkers (2004), LF has an effect

397 in the cell cycle machinery, by influencing the genetic expression of some of its key  
398 components. LF is known to apprehend cancer cells in the G1-phase or alternatively  
399 forcing them to enter the latency phase G0-phase (Ward et al., 2005). The cell cycle  
400 machinery is mainly regulated by cyclin-dependent kinases (**cdks**) that are responsible  
401 for the progression through the cell cycle phases (Damiens et al., 1999). In addition, the  
402 retinoblastoma protein (**pRb**) is known to inhibit the cycle progression, although it is  
403 frequently phosphorylated by cdks, causing its loss of functionality (Damiens et al.,  
404 1999). The mechanism by which LF inhibits cell proliferation may be related with the  
405 fact that it inhibits cdks and cyclin E genetic expression (Xiao et al., 2004).  
406 Furthermore, LF has been reported to increase the expression of pRb, p21 and p27,  
407 known as inhibitors of the cell cycle (Rodrigues et al., 2009; Damiens et al., 1999).  
408 Also, it is important to notice that LF possesses an estrogen response element (**ERE**) in  
409 its gene. The ERE is probably a key component for the anti-proliferation effect of LF, as  
410 it confers LF the ability to interfere in genetic expression (Stokes et al., 2004).  
411 According to Baumrucker and collaborators (2000), LF also affects the cell growth by  
412 interacting with epidermal growth factor binding protein 3 (**EGFBP3**). EGFBP3 usually  
413 binds with the epidermal growth factor (**EGF**), exerting a protective effect, thus helping  
414 cellular growth. Competing with EGF by EGFBP3, LF prevents the stimulation of cell  
415 growth. In spite of the information gathered in this preliminary study, further research  
416 should be conducted to determine the expression of cell cycle regulatory proteins as a  
417 starting point to disclose the mechanisms by which LF exerts its effect in cell  
418 proliferation. When a cancer has developed, it is beneficial that food components can  
419 slow the rate of tumor growth; therefore LF effect on cell growth rates should be  
420 assessed as well as a long-term treatment, since the daily intake of milk and dairy  
421 products might not be enough to produce an immediate physiological relevant dose  
422 (Freiburghaus et al., 2009).

423 Cell migration is a key mechanism in the development of metastasis and tissue  
424 invasion. Therefore, any agent that can impair cell migration will yield a positive  
425 response in cancer treatment and recurrence. Fig. 3 and 4 showed that LF decreases the  
426 migration of both cell lines used, even for HS578T cells (Fig. 3) that have a higher  
427 migration potential (mainly due to the lack of estrogen receptor expression (**ER-**)) as  
428 compared to T47D (Fig. 4) for which the effect was more pronounced. This may be  
429 related with the fact that LF interacts with cadherins and integrins (Von Schlippe et al.,  
430 2000), which in part can explain some cell detachment that occurred for T47D cells.

431 Although these results would be more relevant if a greater effect had been observed for  
432 HS578T cells, as these are ER- and correspond to more aggressive type of tumors for  
433 which the existent therapy is not very efficient, this study is one of the first assessments  
434 on the effect of LF in migration (Giacontti, 2006; Neve et al., 2006; Ariazi et al., 2002).  
435 Moreover, the results obtained for T47D suggest that a combination of estrogen and LF  
436 could be further explored for breast cancer therapeutics.

437 Although further research on the LF effects on breast cancer is required, the  
438 findings of this study are very promising, and of particular relevance for the food  
439 industry in general. The intake of milk and dairy products, or even food products  
440 enriched with LF, may be in the future a natural way of preventing breast cancer or  
441 enhancing patients' treatment.

442

443

## CONCLUSIONS

444

445 In conclusion, from the results gathered in this work it was found that a 48 h exposure  
446 to 12.5  $\mu$ M LF decreases cell viability and proliferation for both cell lines studied.  
447 Furthermore, these conditions promoted an increase in apoptosis. Although the  
448 mechanisms of LF action are still not fully understood, there is evidence pointing to its  
449 ability to interact with some receptors, as well as to modulate genetic expression of  
450 several molecules that are vital to the cell cycle and apoptosis machinery. Moreover, LF  
451 was shown to decrease the ability of both cell lines to migrate. LF has a great potential  
452 to be used in breast cancer treatment.

453

454

## ACKNOWLEDGMENTS

455

456

457 The authors acknowledge IPATIMUP for kindly providing the breast cancer cell lines  
458 used in this work.

459

460

## REFERENCES

- 461 Ariazi, E. A., G. M. Clark, and J. E. Mertz. 2002 Estrogen-related receptor alfa and estrogen-  
462 related receptor gama associate with unfavorable and favorable biomarkers, respectively, in  
463 human breast cancer. *Cancer Research* 62: 6510-6518  
464  
465 Babina, E., D. Semenov, V. Buneva, and G. Nevisnkii. 2005. Human milk lactoferrin  
hydrolyses nucleoside-5'-triphosphates. *Mol. Biol.* 39:513-520

466  
467 Baumrucker, C. 2000. Mammary mechanisms for lactoferrin: interactions with IGFBP3.  
Biotechnol. Agron. Soc. Environ. 4:5-12

468  
469 Bezault, J., R. Bhimani, J. Wiprovnick, and P. Furmanski. 1994. Human lactoferrin inhibits  
470 growth of solid tumors and development of experimental metastases in mice. *Cancer Res.*  
54:2310–2312

471  
472 Damiens, E., I. Yazidi, J. Mazurier, I. Duthile, G. Spik, and Y. Boilly-Marer. 1999. Lactoferrin  
473 inhibits G1 cyclin-dependent kinases during growth arrest of human breast carcinoma cells. *J.*  
Cell. Biochem. 74:486-498

474  
475 Ferguson, L. 2009. Nutrigenomics approaches to functional foods. *J. Am. Diet. Assoc.* 109:452-  
458

476  
477 Freiburghaus, C., B. Janicke, H. Lindmark-Månsson, S. M. Oredsson, and M. A. Paulsson.  
478 2009. Lactoferricin treatment decreases the rate of cell proliferation of a human colon cancer  
479 cell line. *J. Dairy Sci.* 92:2477–2484.

480  
481 Fujita, K. -I, E. Matsuda, K. Sekine, M. Iigo, and H. Tsuda. 2004 Lactoferrin enhances Fas  
482 expression and apoptosis in the colon mucosa of azoxymethane-treated rats. *Carcinogenesis.*  
25(10): 1961-1966

483  
484 Giacconti V. 2006. Breast cancer markers. *Cancer Lett.* 243:145-159

485  
486 Gill, H. S., F. Doull, K. J. Rutherford, and M. L. Cross. 2000. Immunoregulatory peptides in  
487 bovine milk. *Br. J. Nutr.* 84 (Suppl. 1):S111–S117

488  
489 Hakansson, A., B. Zhivotovski, S. Orrenius, H. Sabharwal, and C. Svanbory. 1995. Apoptosis  
490 induced by a human milk protein. *Proc. Natl. Ac. Sci.* 92:8064-8068

491  
492 Hanahan, D., and R. Weinberg. 2000. The hallmarks of cancer. *Cell* 100:57-70

493  
494 Iigo, M., D. Alexander, N. Long, J. Xu, K. Fukamachi, M. Futakuchi, M. Takase, and H. Tsuda.  
495 2009. Anticarcinogenesis pathways activated by bovine lactoferrin in the murine small intestine.  
Biochimie 91:86-101

496  
497 Jacobs, D., M. Gross, and L. Tapsell. 2009. Food synergy: an operational concept for  
498 understanding nutrition. *Am. J. Clin. Nutr.* 89:1543S-1548S

499  
500 Jemal, A., R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun. 2009. Cancer Statistics, 2009. *CA*  
501 *Cancer J. Clin.* 59:225-249

502  
503 Korhonen, H., and A. Pihlanto. 2006. Bioactive peptides: Production and functionality. *Int.*  
504 *Dairy J.* 16:945–960

505  
506 Legrand, D., E. Ellass, M. Carpentier, and J. Mazurier. 2005. Lactoferrin: a modulator of  
507 immune and inflammatory responses. *Cell. Mol. Life Sci.* 62:2549–2559

508  
509 Mader, J., J. Salsman, D. Conrad, and D. Hoskin. 2005. Bovine lactoferricin selectively induces  
510 apoptosis in human leukaemia and carcinoma cell lines. *Mol. Cancer Ther.* 4:612-624

511  
512 Marshall, K. 2004. Therapeutic applications of whey protein. *Alt. Med. Rev.* 9(2):136-156

513  
514 McCabe-Sellers, B., C. Chenard, D. Lovera, C. Champagne, M. Bogle, and J. Kaput. 2009.  
515 Readiness of food composition databases and food component analysis systems for  
516 nutrigenomics. *J. Food Comp. Anal.* 22:S57-S62

517  
518 Neve, R. M., K. Chin, J. Fridlyand, J. Yeh, F. L. Baehner, T. Fevr, L. Clark, N. Bayani, J. -P.  
519 Coppe, F. Tong, T. Speed, P. T. Spellman, S. DeVries, A. Lapuk, N. J. Wang, W. -L. Kuo, J. L.  
520 Stilwell, D. Pinkel, D. G. Albertson, F. M. Waldman, F. McCormick, R. B. Dickson, M. D.  
521 Johnson, M. Lippman, S. Ethier, A. Gazdar, and J. W. Gray. 2006. A collection of breast cancer  
cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell* 10:515-527



511 Pan, Y., M. Rowney, P. Guo, and P. Hobman. 2007. Biological properties of lactoferrin: an  
512 overview. *Aust. J. Dairy Technol.* 62:31-42

513 Perdigon, G., A. De Moreno de LeBlanc, J. Valdez, and M. Rachid. 2002. Role of yoghurt in  
514 the prevention of colon cancer. *Eur. J. Clin. Nutr.* 56:65–68

515 Petricoin, E., and L. Liotta. 2003. Clinical applications of proteomics. *J. Nutr.* 133:2476–2484

516  
517 Rodrigues, L.R., J. Teixeira, F. Schmitt, M. Paulsson, and H. Lindmark-Mansson. 2009.  
Lactoferrin and cancer prevention. *Crit. Rev. Food Sci. Nutr.* 49(3):203-217

518 Roy, M., Y. Kuwabara, K. Hara, Y. Watanabe, and Y. Tamai. 2002. Peptides from the N-  
519 terminal end of bovine lactoferrin induces apoptosis in human leukemic (HL60) cells. *J. Dairy*  
520 *Sci.* 85:2065-2074

521 Sakai, T., Y. Banno, Y. Kato, Y. Nazawa, and M. Kawaguchi. 2005. Pepsin-digested bovine  
522 lactoferrin induces apoptotic cell death with JNK/SAPK activation in oral cancer. *J. Pharmacol.*  
523 *Sci.* 98:41-48

524 Schiff, R., and C. Osborne. 2005. New insight into estrogen receptor  $\alpha$  function and its  
525 implication for endocrine therapy resistance in breast cancer. *Breast Cancer Res.* 7:208-211

526 Stokes, K., B. Alston-Mills, and C. Teng. 2004. Estrogen response element and the promoter  
527 context of the human and mouse lactoferrin genes influence estrogen receptor alpha-mediated  
528 transactivation activity in mammary gland cells. *J. Mol. Endocrinol.* 83:315-334

529 Teng, C. 2006. Factors regulating lactoferrin gene expression. *Biochem. Cell Biol.* 84:263-267

530 Tomita, M., H. Wakabayashi, K. Yamauchi, S. Teraguchi, and H. Hayasawa. 2002. Bovine  
531 lactoferrin and lactoferricin derived from milk: production and applications. *Biochem. Cell*  
532 *Biol.* 80:109-112

533 Tomita, M., M. Takase, W. Bellamy, and S. Shimura. 1994. A review: the active peptide of  
534 lactoferrin. *Acta Paediatr. Jpn.* 36:585

535 Troost, F. J., J. Steijns, W. H. M. Saris, and R.-J. M. Brummer. 2001. Gastric digestion of  
536 bovine lactoferrin in vivo in adults. *J. Nutr.* 131:2101–2104

537  
538 Tsuda, H., K. Sekine, K. Fujitaand, and M. Iigo. 2002. Cancer prevention by bovine lactoferrin  
539 and underlying mechanisms - a review of experimental and clinical studies. *Biochem. Cell Biol.*  
80:131-136

540  
541 Tsuda, H., K. Sekine, Y. Ushida, T. Kuhara, N. Takasuka, M. Iigo, B. S. Hans, and M. A.  
542 Moore. 2000. Milk and dairy products in cancer prevention: focus on bovine lactoferrin. *Mutat.*  
*Res.* 462:227-233

543 Tsuda, H., T. Kozu, G. Iinuma, Y. Ohashi, Y. Saito, D. Saito, T. Akasu, D. B. Alexander, M.  
544 Futakuchi, K. Fukamachi, J. Xu, T. Kakizoe, and M. Iigo. 2010. Cancer prevention by bovine  
545 lactoferrin: from animal studies to human trial. *Biomaterials* 23:399–409

546  
547 Tsuda, H., Y. Ohshima, H. Nomoto, K. Fujita, E. Matsuda, M. Iigo, N. Takasuka, and M. A.  
548 Moore. 2004. Cancer prevention by natural compounds. *Drug Metab. Pharmacokinet.* 19:245-  
263

549  
550 Von Schlippe, M., J. F. Marshall, P. Perry, M. Stone, A. J. Zhu, and I. R. Hart. 2000. Functional  
551 interaction between E-cadherin and  $\alpha$ v-containing integrins in carcinoma cells. *J. Cell Sci.*  
113:425-437

552  
553 Wakabayashi, H., K. Yamauchi, and M. Takase. 2006. Lactoferrin research, technology and  
applications. *Int. Dairy J.* 16:1241–1251.

554  
555 Ward, P., E. Paz, and O. Conneely. 2005. Multifunctional roles of lactoferrin: a critical  
overview. *Cell. Mol. Life Sci.* 62:2540-2548

- 556  
557 Werner, H., J. Franke, and R. Vermes. 2005. Apoptosis and proliferation in breast cancer cells  
cultured in vitro: effects on SERMs. *Climacteric* 83:294-299
- 558  
559 Xiao, Y., C. Monitto, K. Minhas, and D. Sidranski. 2004. Lactoferrin down-regulates G1 cyclin-  
560 dependent kinases during growth arrest of head and neck cancer cells. *Clin. Cancer Res.*  
10:8683-8686
- 561 Xu, X. X., H. R. Jiang, H. B. Li, T. N. Zhang, Q. Zhou, and Q. Liu. 2010. Apoptosis of stomach  
562 cancer cell SGC-7901 and regulation of Akt signaling way induced by bovine lactoferrin. *J.*  
563 *Dairy Sci.* (6):2344-2350
- 564 Zemann, N., P. Klein, E. Wetzell, F. Huettinger, and M. Huettinger. 2010. Lactoferrin induces  
565 growth arrest and nuclear accumulation of Smad-2 in HeLa cells. *Biochimie* 92:880-884  
566
- 567

568  
569  
570  
571  
572  
573  
574  
575  
576

**Table 1.** Effect of LF treatment (0.125, 6.25, 12.5 and 125  $\mu\text{M}$ ) on HS578T and T47D cells for different exposure times (24, 48 and 72 h), by two complementary tests: TB dye method and the bio-reduction of the MTS reagent. For both cell lines and tests, the number of viable cells after treatment with PBS (no LF added) as control for each exposure time was set at 100%. Results represent the percentage of viable cells for each condition. Means ( $\pm$  standard deviation) were calculated from 3 independent cultures and 8 measures for each culture. Significant changes to control: \*:  $p < 0.05$ ; \*\*:  $p < 0.005$ ; \*\*\*:  $p < 0.0005$  (two-tailed unpaired Student's *t*-test).

Trypan Blue Method						
[LF] $\mu\text{M}$	HS578T			T47D		
	24 h	48 h	72 h	24 h	48 h	72 h
<b>0.125</b>	92.9 $\pm$ 6.0 *	91.6 $\pm$ 3.9 **	41.6 $\pm$ 8.6 **	95.6 $\pm$ 5.2 *	93.4 $\pm$ 5.2	97.9 $\pm$ 5.7
<b>6.25</b>	75.4 $\pm$ 7.3 *	75.5 $\pm$ 4.0 ***	54.1 $\pm$ 5.9 **	78.5 $\pm$ 2.4 **	69.5 $\pm$ 2.4 ***	59.3 $\pm$ 3.1 ***
<b>12.5</b>	69.1 $\pm$ 3.7 ***	81.9 $\pm$ 9.2 *	53.1 $\pm$ 6.3 **	72.4 $\pm$ 7.3 **	59.1 $\pm$ 7.3 ***	46.3 $\pm$ 1.7 ***
<b>125</b>	40.6 $\pm$ 5.8 ***	45.4 $\pm$ 4.9 ***	13.6 $\pm$ 2.5 ***	43.2 $\pm$ 8.6 **	41.6 $\pm$ 8.6 **	18.1 $\pm$ 3.6 ***

MTS Method						
[LF] $\mu\text{M}$	HS578T			T47D		
	24 h	48 h	72 h	24 h	48 h	72 h
<b>0.125</b>	88.5 $\pm$ 5.3 *	77.1 $\pm$ 3.7 ***	30.2 $\pm$ 4.1 ***	82.3 $\pm$ 4.3 **	53.9 $\pm$ 2.7 **	28.4 $\pm$ 3.2 ***
<b>6.25</b>	60.6 $\pm$ 4.1 **	50.3 $\pm$ 1.9 ***	4.5 $\pm$ 3.3 ***	75.3 $\pm$ 3.2 ***	40.9 $\pm$ 4.3 ***	11.3 $\pm$ 2.9 ***
<b>12.5</b>	67.8 $\pm$ 2.2 ***	39.5 $\pm$ 2.2 ***	17.5 $\pm$ 7.1 ***	63.7 $\pm$ 5.1 **	32.4 $\pm$ 5.3 ***	8.2 $\pm$ 2.3 ***
<b>125</b>	25.7 $\pm$ 3.5 ***	13.3 $\pm$ 4.4 ***	0.1 $\pm$ 3.2 ***	47.3 $\pm$ 2.6 ***	21.3 $\pm$ 4.2 ***	7.3 $\pm$ 4.1 ***

577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592

593

## FIGURE CAPTIONS

594

595

**Figure 1. Apoptosis:** effect of LF treatment (0.125, 6.25, 12.5 and 125  $\mu\text{M}$ ) on: (A) HS578T and (B) T47D apoptosis levels for different exposure times (24, 48 and 72 h). Results represent an average of 3 independent cultures and 8 measures for each culture. Significant changes to control: \*:  $p < 0.05$ ; \*\*:  $p < 0.005$ ; \*\*\*:  $p < 0.0005$  (two-tailed unpaired Student's t-test).

600

601

**Figure 2. Cell proliferation:** effect of LF treatment (12.5  $\mu\text{M}$ ; 48 h exposure). Control samples (with no LF added) were included for both cell lines. T47D: Control samples: (A) - total nuclei, (B) - nuclei in proliferation; Treated samples: (C) - total nuclei, (D) - nuclei in proliferation. HS578T: Control samples: (E) - total nuclei, (F) - nuclei in proliferation; Treated samples: (G) - total nuclei, (H) - nuclei in proliferation. Magnification used: 40X. Scale bar 10  $\mu\text{m}$ .

607

608

**Figure 3. Migration:** effect of LF treatment (12.5  $\mu\text{M}$ ; 48 h exposure) on HS578T cells. Exposure time to LF: 0 h - (A); exposure time to LF: 48 h - (B). Table summarizes the distances ( $\mu\text{m}$ ) over time between the front cells in each edge of the wound and the results represent an average of 3 independent cultures and 9 measures for each culture. Control samples (with no LF added) were included. Magnification used: 40X. Scale bar 10  $\mu\text{m}$ .

614

615


**Figure 4. Migration:** effect of LF treatment (12.5  $\mu\text{M}$ ; 48 h exposure) on T47D cells. Exposure time to LF: 0 h - (A); exposure time to LF: 48 h - (B). Table summarizes the distances ( $\mu\text{m}$ ) over time between the front cells in each edge of the wound and the results represent an average of 3 independent cultures and 9 measures for each culture. Control samples (with no LF added) were included. Magnification used: 40X. Scale bar 10  $\mu\text{m}$ .

621


622

623

624



625



626

627

628


629

630

631

Figure 1.

632  
633




634  
635

636  
637  
638  
639  
640  
641  
642

Figure 2.

643  
644  
645  
646




Time (h)	[Distance $\mu\text{m}$ ]	
	0 $\mu\text{M}$ LF	12.5 $\mu\text{M}$ LF
0	179 $\pm$ 2	167 $\pm$ 3
3	172 $\pm$ 1	162 $\pm$ 3
6	100 $\pm$ 3	116 $\pm$ 4
9	98 $\pm$ 2	109 $\pm$ 1
24	72 $\pm$ 3	82 $\pm$ 6
27	50 $\pm$ 12	48 $\pm$ 2
30	20 $\pm$ 10	27 $\pm$ 2
34	13 $\pm$ 6	26 $\pm$ 4
48	0 $\pm$ 1	6 $\pm$ 3

647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672

**Figure 3.**

673  
674



Time (h)	[Distance $\mu\text{m}$ ]	
	0 $\mu\text{M}$ LF	12.5 $\mu\text{M}$ LF
0	382 $\pm$ 8	380 $\pm$ 3
3	372 $\pm$ 19	379 $\pm$ 2
6	257 $\pm$ 14	366 $\pm$ 3
9	222 $\pm$ 12	373 $\pm$ 9
24	166 $\pm$ 12	380 $\pm$ 10
27	116 $\pm$ 13	390 $\pm$ 6
30	103 $\pm$ 9	377 $\pm$ 6
34	87 $\pm$ 5	377 $\pm$ 4
48	87 $\pm$ 5	386 $\pm$ 4

675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704

Figure 4.